74 Breast Cancer Clinical Trials in Boston, NY (2026)

Q: How do I join a clinical trial in Boston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you.

Recruiting Breast Cancer Studies in Boston

NCT06934239Recruiting

A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

The goal of this clinical trial is to compare patient-centered outcomes when screening digital breast tomosynthesis (DBT) exams are interpreted with versus without a leading FDA-cleared artificial int...

Boston, NY400,000 participantsJonsson Comprehensive Cancer Center

View Study Details

NCT06888388Recruiting

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

Patients with a germline pathogenic variant (GPV) in high-penetrance breast cancer susceptibility genes who are considering risk reducing mastectomy (RRM) often strongly desire to keep their nipple ar...

Boston, NY4,700 participantsSir Mortimer B. Davis - Jewish General Hospital

View Study Details

NCT07597837Recruiting

Oncoplastic Surgery Outcomes Database

This is a retrospective and prospective chart review of surgical outcomes and collecting patient satisfaction outcomes using validated surveys for oncoplastic breast surgery and Goldilocks mastectomy....

Boston, NY1,500 participantsTufts Medical Center

View Study Details

NCT06757634Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced o...

Boston, NY1,180 participantsCelcuity Inc

View Study Details

NCT06275126Recruiting

Optimizing Surgical Decisions in Young Adults With Breast Cancer

The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evalua...

Boston, NY800 participantsWeill Medical College of Cornell University

View Study Details

NCT06551220Recruiting

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

The purpose of this observational study is to learn about the HER2 heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer. The main question it aims to answer ...

Boston, NY800 participantsSun Yat-sen University

View Study Details

NCT05696626Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- ...

Boston, NY600 participantsSermonix Pharmaceuticals Inc.

View Study Details

NCT02610439Recruiting

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for bre...

Boston, NY575 participantsNational Cancer Institute (NCI)

View Study Details

NCT07114601Recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-rele...

Boston, NY421 participantsEli Lilly and Company

View Study Details

NCT06896474Recruiting

SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

Investigators aim to conduct a type 1 hybrid effectiveness-implementation surgeon-level cluster randomized clinical trial (RCT) of a multi-level intervention, a shared decision making training for sur...

Boston, NY402 participantsBeth Israel Deaconess Medical Center

View Study Details

NCT06795529Recruiting

Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

Many people living with metastatic breast cancer face challenging symptoms and frequent medical visits. At the same time, conversations about personal goals, values, and preferences for care may not a...

Boston, NY400 participantsMassachusetts General Hospital

View Study Details

NCT06253871Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that...

Boston, NY383 participantsIambic Therapeutics, Inc

View Study Details

NCT07123649Recruiting

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surve...

Boston, NY364 participantsDana-Farber Cancer Institute

View Study Details

NCT07029399Recruiting

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tum...

Boston, NY361 participantsNiKang Therapeutics, Inc.

View Study Details

NCT05377996Recruiting

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Emi-Le in Participants with Solid Tumors...

Boston, NY360 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT06533826Recruiting

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan fol...

Boston, NY357 participantsAna C Garrido-Castro, MD

View Study Details

NCT02610413Recruiting

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer...

Boston, NY354 participantsNational Cancer Institute (NCI)

View Study Details

NCT04802759Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments be...

Boston, NY316 participantsHoffmann-La Roche

View Study Details

NCT07222215Recruiting

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer....

Boston, NY297 participantsKristina A. Fanucci

View Study Details

NCT05890677Recruiting

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) ...

Boston, NY280 participantsUniversity Hospital, Basel, Switzerland

View Study Details

NCT06726148Recruiting

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. ...

Boston, NY280 participantsNovartis Pharmaceuticals

View Study Details

NCT05535192Recruiting

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are recei...

Boston, NY270 participantsDana-Farber Cancer Institute

View Study Details

NCT04230109Recruiting

Sacituzumab Govitecan In TNBC

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacitu...

Boston, NY260 participantsMassachusetts General Hospital

View Study Details

NCT06123988Recruiting

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

The purpose of this study is to test if four different programs (prolonged overnighting fasting alone, exercise alone, a combination of prolonged overnight fasting and exercise, or general health educ...

Boston, NY260 participantsUniversity of Miami

View Study Details

NCT05950945Recruiting

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who ar...

Boston, NY250 participantsDaiichi Sankyo

View Study Details

NCT05683418Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study e...

Boston, NY241 participantsTotus Medicines

View Study Details

NCT06993844Recruiting

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors...

Boston, NY233 participantsEnsem Therapeutics

View Study Details

NCT05894239Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination wit...

Boston, NY230 participantsHoffmann-La Roche

View Study Details

NCT04030507Recruiting

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain)....

Boston, NY214 participantsBrigham and Women's Hospital

View Study Details

NCT06099769Recruiting

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor...

Boston, NY201 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05467891Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast can...

Boston, NY200 participantsOana Danciu

View Study Details

NCT06507930Recruiting

The COMPASSION Study

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between pa...

Boston, NY200 participantsDana-Farber Cancer Institute

View Study Details

NCT06184750Recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well establi...

Boston, NY200 participantsNational Cancer Institute (NCI)

View Study Details

NCT05508906Recruiting

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis ...

Boston, NY190 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT06784193Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltran...

Boston, NY180 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT06042569Recruiting

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

This phase II trial tests how well dose-reduced docetaxel combined with cyclophosphamide works in treating older women with early stage (stage I-III) HER2 negative breast cancer vulnerable to toxicity...

Boston, NY174 participantsCity of Hope Medical Center

View Study Details

NCT05872295Recruiting

IKS014 in Advanced Solid Tumors That Express HER2

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targe...

Boston, NY165 participantsIksuda Therapeutics Ltd.

View Study Details

NCT02610426Recruiting

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breas...

Boston, NY162 participantsNational Cancer Institute (NCI)

View Study Details

NCT05735080Recruiting

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to eval...

Boston, NY150 participantsIncyclix Bio

View Study Details

NCT05523947Recruiting

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastati...

Boston, NY147 participantsYuhan Corporation

View Study Details

NCT07546812Recruiting

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based combinations in in par...

Boston, NY120 participantsGilead Sciences

View Study Details

NCT04986579Recruiting

Scalp Cooling in MBC

This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment wi...

Boston, NY120 participantsDana-Farber Cancer Institute

View Study Details

NCT04468061Recruiting

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts ...

Boston, NY110 participantsDana-Farber Cancer Institute

View Study Details

NCT05468034Recruiting

Exercise in Metastatic Breast Cancer: EMBody

The purpose of this study is to study exercise in a novel population with indolent MBC (no progression on current therapy in prior 12 months and not receiving cytotoxic chemotherapy). The study team h...

Boston, NY100 participantsIndiana University

View Study Details

NCT04841148Recruiting

Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor dissemin...

Boston, NY96 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT05573126Recruiting

Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, an...

Boston, NY95 participantsEllipses Pharma

View Study Details

NCT04553770Recruiting

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab...

Boston, NY88 participantsJonsson Comprehensive Cancer Center

View Study Details

NCT06686394Recruiting

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cance...

Boston, NY81 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07513311Recruiting

A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer

The purpose of this study is to explore the feasibility and acceptability of a nurse-led, coping, and supportive care intervention for patients with triple-negative breast cancer. The intervention aim...

Boston, NY75 participantsMassachusetts General Hospital

View Study Details

NCT05386108Recruiting

Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-pos...

Boston, NY73 participantsStemline Therapeutics, Inc.

View Study Details

NCT06439693Recruiting

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

The purpose of this study is to test the safety and effectiveness of a sequence of drugs (a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Deruxtecan, followed by Tucatinib plus Ado-T...

Boston, NY72 participantsDana-Farber Cancer Institute

View Study Details

NCT07198724Recruiting

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

The goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-u...

Boston, NY65 participantsKristina A. Fanucci

View Study Details

NCT05304962Recruiting

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR...

Boston, NY64 participantsRegor Pharmaceuticals Inc.

View Study Details

NCT05608252Recruiting

VS-6766+Abema+Fulv in Met HR+/HER- BC

This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. ...

Boston, NY63 participantsAdrienne G. Waks

View Study Details

NCT05795101Recruiting

TRUDI: TDXD+Durva in HER2+/Low IBC

The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Hum...

Boston, NY63 participantsFilipa Lynce, MD

View Study Details

NCT04115306Recruiting

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breas...

Boston, NY61 participantsPhoenix Molecular Designs

View Study Details

NCT07553572Recruiting

Remote Monitoring and Symptom Management Digital Application

The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment. The main question\[s\] it aims to answer are: ...

Boston, NY60 participantsPatrick C. Johnson, MD

View Study Details

NCT05501704Recruiting

ETHAN - ET for Male BC

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male...

Boston, NY60 participantsJose Pablo Leone

View Study Details

NCT06176261Recruiting

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the ...

Boston, NY58 participantsSarah Sammons, MD

View Study Details

NCT05422794Recruiting

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatm...

Boston, NY57 participantsNational Cancer Institute (NCI)

View Study Details

NCT06908928Recruiting

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-...

Boston, NY52 participantsMabwell (Shanghai) Bioscience Co., Ltd.

View Study Details

NCT04636710Recruiting

Refining Local-Regional Therapy for IBC

This Feasibility study is trying to determine: * If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients ...

Boston, NY50 participantsDana-Farber Cancer Institute

View Study Details

NCT06923527Recruiting

Circulating Tumor DNA

This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period ...

Boston, NY50 participantsYale University

View Study Details

NCT06827613Recruiting

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Comb...

Boston, NY50 participantsMarengo Therapeutics, Inc.

View Study Details

NCT06322888Recruiting

Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)

The goal of this study is to learn more about how exercise might lower the risk of developing breast cancer in women with dense breast tissue by studying changes that occur in breast tissue and blood ...

Boston, NY46 participantsDana-Farber Cancer Institute

View Study Details

NCT05372640Recruiting

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

This phase I trial tests the safety, side effects, and best dose of ZEN003694 when given together with abemaciclib in treating patients with NUT carcinoma, breast cancer or other solid tumors that hav...

Boston, NY45 participantsNational Cancer Institute (NCI)

View Study Details

NCT04305834Recruiting

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to othe...

Boston, NY43 participantsCity of Hope Medical Center

View Study Details

NCT06052488Recruiting

Strength After Breast Cancer

The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among w...

Boston, NY40 participantsMGH Institute of Health Professions

View Study Details

NCT04434040Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulatin...

Boston, NY40 participantsDana-Farber Cancer Institute

View Study Details

NCT07137416Recruiting

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

This phase I trial tests the safety, side effects, and best dose of pidnarulex in combination with trastuzumab deruxtecan in treating patients with breast cancer and other solid tumors that express va...

Boston, NY36 participantsNational Cancer Institute (NCI)

View Study Details

NCT06758102Recruiting

Dance Study for Post-surgical Pain in Breast Cancer Survivors

The purpose of this study is to examine how a 12-week, virtual dance program may improve pain and quality of life in participants with persistent post-surgical pain, or PPSP, following mastectomy or l...

Boston, NY30 participantsDana-Farber Cancer Institute

View Study Details

NCT04724499Recruiting

Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy

The purpose of this research is to determine whether a 16-week high intensity interval training (HIIT) exercise program will improve brain health among women undergoing chemotherapy and also improve c...

Boston, NY30 participantsDana-Farber Cancer Institute

View Study Details

NCT03990896Recruiting

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation....

Boston, NY30 participantsMassachusetts General Hospital

View Study Details

NCT06488378Recruiting

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and P...

Boston, NY20 participantsDana-Farber Cancer Institute

View Study Details

About Breast Cancer Clinical Trials in Boston

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 74 breast cancer clinical trials recruiting participants in Boston, NY. These studies are seeking a combined 420,800 participants. Research is being sponsored by Jonsson Comprehensive Cancer Center, Sir Mortimer B. Davis - Jewish General Hospital, Tufts Medical Center and 46 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Boston — FAQ

Are there breast cancer clinical trials in Boston?

Yes, there are 74 breast cancer clinical trials currently recruiting in Boston, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 74 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 13, 2026 from ClinicalTrials.gov